Biomarker Discovery in Medical and Health Contexts Using Metabolomics

Guest Editors:

Dr. François Fenaille
Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, MetaboHUB, F-91191 Gif sur Yvette, France

Dr. Florence Castelli
Département Médicaments et Technologies pour la Santé (DMTS), University Paris-Saclay, CEA, INRAE, MetaboHUB, 91191 Gif sur Yvette, France

Dr. Benoit Colsch
Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, MetaboHUB, F-91191 Gif sur Yvette, France

Deadline for manuscript submissions:
closed (31 March 2022)

Message from the Guest Editors

Research and developments in biomarker discovery are central in modern health care for personalized and precision medicine. Omics approaches are particularly relevant and useful tools to identify new molecular biomarkers to improve the diagnosis and prognosis of various diseases, as well as to evaluate treatment efficacy. In this context, metabolomics represents an attractive strategy for profiling in patient biofluids or tissues samples a large panel of low molecular weight molecules closely related to (patho)physiological conditions and treatment response phenotypes.

This Special Issue of the *International Journal of Translational Medicine* will be devoted to the development and use of metabolomics approaches at both the translational and the clinical level. Topics may include but are not limited to metabolomics for biomarker discovery of specific diseases or in a personalized medicine context, molecular understanding of pathophysiological contexts, methodological developments (e.g., for broadening metabolome coverage or implementation of more sensitive approaches), and approaches for large-scale analysis of human cohorts.

Special Issue